JPRN-UMIN000026630招募中未知
Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin,versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes Mellitus who have Undergone Percutaneous Coronary Intervention: Open-label Randomized Parallel-group Trial - STILL-GLORY trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria were (1) type 1 diabetes, (2) severe complications of diabetes (3) hypersensitivity to the components of dulaglutide or luseogliflozin (4) severe liver, renal dysfunction (5) severe heart failure (NYHA 3,4) (6) pregnant or nursing women and those who might be pregnant (7) Familial Hypercholesterolemia: FH (8) Treatment with PCSK-9 inhibitor (9) any patients whom the investigators judgd to be inappropriate for this study.
研究者
相似试验
招募中
3 期
Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin, versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes MellitusJPRN-jRCTs031180408Aso Yoshimasa200
招募中
4 期
Efficacy of SGLT2 inhibitor for Non-Alcoholic Fatty Liver Diseaseon Alcoholic Fatty Liver DiseaseC06.552.241.519C18.452.394.750.149ObesityType 2 Diabetes MellitusRBR-48rxwbCentro Educacional Hyarte
已完成
不适用
Comparative trial of SGLT2-inhibitor (Canagliflozin) and sulfonylurea (Glimepiride) for patients with DMDiabetes mellitus type 2JPRN-UMIN000024922Sekino Hospital30
已完成
Unknown
Prospective observational study of tofogliflozin in patients with type 2 diabetesType 2 DiabetesJPRN-jRCT1090220212agoya Medical Association600
已完成
不适用
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50